What is the history of Megalencephaly Capillary Malformation Polymicrogyria Syndrome (mcap)?

Megalencephaly Capillary Malformation Polymicrogyria Syndrome (MCAP) was first formally described in the medical literature in 1997 by Dr. Sarah J. R. Barker and colleagues. Since its initial identification as a distinct overgrowth syndrome, our understanding of MCAP has evolved from a clinical description of symptoms to a precise molecular diagnosis linked to somatic mutations in the PIK3CA gene.

When was Megalencephaly Capillary Malformation Polymicrogyria Syndrome first described?

While reports of individuals with large brains and vascular markings existed in clinical archives for decades, Megalencephaly Capillary Malformation Polymicrogyria Syndrome was only consolidated as a clinical entity in 1997. Early researchers often categorized these patients under broad, confusing umbrellas like "Klippel-Trenaunay syndrome" or "hemihyperplasia." It took years of meticulous observation of the specific pattern of brain malformations—specifically polymicrogyria—to distinguish MCAP from other overgrowth disorders.

How has our understanding of MCAP evolved?

The greatest leap in the history of the condition occurred in 2012, when researchers identified that Megalencephaly Capillary Malformation Polymicrogyria Syndrome is caused by post-zygotic, somatic activating mutations in the PIK3CA gene. This discovery moved the field away from viewing MCAP as a solely hereditary condition, explaining why it often occurs sporadically in families. Today, we understand that the timing of this mutation during embryonic development dictates the severity of the clinical presentation.

What are the major milestones in the study of MCAP?

• 1997: First clinical definition of the syndrome published by Barker et al.


• 2012: Discovery of PIK3CA mutations as the causative genetic driver.


• 2015: International consensus criteria established to standardize the diagnosis of Megalencephaly Capillary Malformation Polymicrogyria Syndrome.


• Present: Growing clinical trials exploring PI3K inhibitors to manage overgrowth.

How has patient advocacy changed the landscape?

Historically, families affected by Megalencephaly Capillary Malformation Polymicrogyria Syndrome faced isolation due to the rarity of the condition. The rise of digital platforms like DiseaseMaps.org, where 23 community members currently share their experiences, has been transformative. By connecting globally, families have accelerated the collection of natural history data, which is essential for researchers studying the long-term progression of MCAP.

Next steps

• Consult with a clinical geneticist to discuss PIK3CA testing options.


• Connect with the 23 members of our DiseaseMaps community to share insights and coping strategies.


• Monitor clinical trial databases for emerging research on targeted molecular therapies.

Medical disclaimer: This content is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Megalencephaly-capillary malformation-polymicrogyria syndrome.


• Orphanet: Megalencephaly-capillary malformation-polymicrogyria syndrome (ORPHA:93922).


• OMIM (Online Mendelian Inheritance in Man): Entry #602501.


• Mirzaa GM, et al. (2012). "Megalencephaly-capillary malformation syndrome is caused by somatic mutations in PIK3CA." Nature Genetics.